Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multiple myeloma. METHODS: Of 351 patients who had received at least one previous antimyeloma therapy, 176 were randomly assigned to receive 25 mg of oral lenalidomide and 175 to receive placebo on days 1 to 21 of a 28-day cycle. In addition, all patients received 40 mg of oral dexamethasone on days 1 to 4, 9 to 12, and 17 to 20 for the first four cycles and subsequently, after the fourth cycle, only on days 1 to 4. Patients continued in the study until the occurrence of disease progression or unacceptable toxic effects. The primary end point was time to progression. RESULTS: The time to progression was significantly longer in the patients who received lenalidomide plus dexamethasone (lenalidomide group) than in those who received placebo plus dexamethasone (placebo group) (median, 11.3 months vs. 4.7 months; P<0.001). A complete or partial response occurred in 106 patients in the lenalidomide group (60.2%) and in 42 patients in the placebo group (24.0%, P<0.001), with a complete response in 15.9% and 3.4% of patients, respectively (P<0.001). Overall survival was significantly improved in the lenalidomide group (hazard ratio for death, 0.66; P=0.03). Grade 3 or 4 adverse events that occurred in more than 10% of patients in the lenalidomide group were neutropenia (29.5%, vs. 2.3% in the placebo group), thrombocytopenia (11.4% vs. 5.7%), and venous thromboembolism (11.4% vs. 4.6%). CONCLUSIONS: Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma. (ClinicalTrials.gov number, NCT00424047 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [31]
In the citing paper
“(iv) they are already a therapeutic reality.[56][57][58][59][60][61][62][63][64][65][66][67]”
From Chasing molecular glue degraders: screening approaches (2022) · cites this paper as [57]
In the citing paper
“A randomized study comparing lenalidomide and dexamethasone to melphalan, thalidomide and prednisone in newly diagnosed patients demonstrated superior 4-year OS (59% versus 51%; HR 0.78, p=0.02) and led to FDA approval in 201527.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“For older patients and/or those unfit for autologous transplantation, the preferred induction approach remains lenalidomide in combination with dexamethasone with or without daratumumab, regimens that are effective and well tolerated in this patient population27,29.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
In the citing paper
“Thalidomide analogues often lead to peripheral blood cytopenias, most commonly neutropenia (28% grade 3/4) and thrombocytopenia (8% grade 3/4)27.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [27]
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Self-citationRichardson, P. G., Blood, E., Mitsiades, C. S., Jagannath, S., Zeldenrust, S. R., Alsina, M., Schlossman, R. L., Rajkumar, S. V., Desikan, K. R., Hideshima, T., et al. (2006) · Blood · doi:10.1182/blood-2006-04-015909 · Cited by 523
Self-citationCombination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma
Rajkumar, S. V., Hayman, S., Gertz, M. A., Dispenzieri, A., Lacy, M. Q., Greipp, P. R., Geyer, S., Iturria, N., Fonseca, R., Lust, J. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.116 · Cited by 512
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
Thalidomide and dexamethasone combination for refractory multiple myeloma
Dimopoulos, M. A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., Vervessou, E., Samantas, E., Papadimitriou, C., Economou, O., et al. (2001) · Annals of Oncology · doi:10.1023/a:1011132808904 · Cited by 283
Self-citationGarcía-Sanz, R., González-Porras, J. R., Hernández, J. M., Polo-Zarzuela, M., Sureda, A., Barrenetxea, C., Palomera, L., López, R., Grande-García, C., Alegre, A., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403322 · Cited by 159
Self-citation
Cited by
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationPalumbo, A., & Anderson, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,326
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationKumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., Kapoor, P., Dingli, D., Hayman, S. R., Leung, N., et al. (2014) · Leukemia · doi:10.1038/leu.2013.313 · Cited by 1,369
“Patients were considered to have high risk disease if FISH studies demonstrated one of the following abnormalities: t(4;14), t(14;16), t(14;20), or loss of p53 gene locus (del 17p or monosomy 17) in the absence of any trisomies.”
BackgroundMethodCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citationCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationLenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
van de Donk, N. W. C. J., Pawlyn, C., & Yong, K. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00135-5 · Cited by 869
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Sonneveld, P., Mateos, M. V., Zamagni, E., Avet-Loiseau, H., Hajek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 877
“The EMA has approved lenalidomide in combination with dexamethasone [25–26] and bortezomib either alone as single agent [27] or in combination with pegylated doxorubicin [28].”
BackgroundSelf-citationKyle, R. A., & Rajkumar, S. V. (2008) · Blood · doi:10.1182/blood-2007-10-078022 · Cited by 855
Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood · doi:10.1182/blood-2010-02-268862 · Cited by 861
“5 mg/L 5 (8) 3 (9) Albumin level, n (%)”
BackgroundInfluentialSelf-citationSonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 801
Self-citationSan-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Self-citationLenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationContinuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
Palumbo, A., Hajek, R., Delforge, M., Kropff, M., Petrucci, M. T., Catalano, J., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 741
“Leukopenia 35 (23) 6 (4) 39 (26) 8 (5) 21 (14) 2 (1)”
InfluentialSelf-citationKumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia · doi:10.1038/leu.2011.196 · Cited by 721
Self-citationRaab, M. S., Podar, K., Breitkreutz, I., Richardson, P. G., & Anderson, K. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60221-x · Cited by 697
McCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
“Mean, months (range)§ 30 (0-108) 13 (0-51) 25 (0-61) 25 (0-55) 39 (27-55) 20 (0-49) 35 (2-71) 29 (0-75) 28 (0-108) 22 (0-86)”
Self-citationGirmenia, C., Cavo, M., Offidani, M., Scaglione, F., Corso, A., Di Raimondo, F., Musto, P., Petrucci, M. T., & Barosi, G. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.01.001 · Cited by 662
Self-citationChen, M., Zhao, Y., Xu, C., Wang, X., Zhang, X., & Mao, B. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3284-y · Cited by 647
Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0603 · Cited by 628
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
“[183] Dimopoulos M, Spencer A, Attal M, et al.”
BackgroundMikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R., Dispenzieri, A., Fonseca, R., Sher, T., Kyle, R. A., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.019 · Cited by 500
“A description of ongoing trends in MM.”
MethodInfluentialVarettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C., & Lazzarino, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp329 · Cited by 487
Self-citationClassification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
“Alongside, lenalidomide (which retains some degree of teratogenicity) was licensed for use in patients with multiple myeloma (also in combination with dexamethasone) and low or intermediate-1 risk myelodysplastic syndromes that harbor 5q cytogenetic abnormalities (as a standalone intervention) [477-480].”
BackgroundMultiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Raje, N., Terpos, E., Willenbacher, W., Shimizu, K., García-Sanz, R., Durie, B., Legieć, W., Krejčí, M., Laribi, K., Zhu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30072-x · Cited by 449
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 423
Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411
Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 392
“Standard treatments include bortezomib or lenalidomide combined with dexamethasone or bortezomib-pegylated liposomal doxorubicin.(45-47,72,73) Rd is highly suggested because it is better tolerated compared with RD.”
BackgroundSelf-citationRichardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Self-citationDimopoulos, M. A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E. A., Petrucci, M. T., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2009) · Leukemia · doi:10.1038/leu.2009.147 · Cited by 363
Self-citationPalumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 352
Self-citationGoy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
“Lenalidomide (Revlimid; Celgene, Summit, NJ) is an immunomodulatory agent initially studied in multiple myeloma and myelodysplastic syndromes.(28-31) Preclinical studies showed antitumor and antiproliferative activities in leukemia and lymphoma, including MCL.”
BackgroundMonoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
“Lenalidomide has remarkable activity in patients with newly diagnosed MM (91) and relapsed refractory MM (92, 93) and it has contributed to significantly improved survival of myeloma patients (94).”
BackgroundInfections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
“When combined with dexamethasone, increase in bacterial infections in patients with relapsed myeloma [27, 28] Adjust dose of lenalidomide in presence of renal dysfunction to avoid excessive myelotoxicity [9] Conditioning regimen for HCT, pre-engraftment Neutropenia and severe alimentary tract mucositis [29]; increase…”
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
“such as bortezomib, thalidomide, and lenalidomide have demonstrated clinical benefit in patients with newly diagnosed(8-13) and relapsed or refractory disease.(5,14-15) Despite these therapeutic advances, long-term control of relapsed/refractory MM remains elusive for most patients.”
BackgroundBone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment
Burgess, J., Ferdousi, M., Gosal, D., Boon, C., Matsumoto, K., Marshall, A., Mak, T., Marshall, A., Frank, B., Malik, R. A., et al. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00168-y · Cited by 306
Multiple myeloma: patient outcomes in real‐world practice
Yong, K., Delforge, M., Driessen, C., Fink, L., Flinois, A., Gonzalez‐McQuire, S., Safaei, R., Karlin, L., Mateos, M., Raab, M. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14213 · Cited by 326
“Given the availability of agents that are effective in relapsed and refractory MM (Singhal et al, 1999; Richardson et al, 2005; Dimopoulos et al, 2007; Weber et al, 2007; Offidani et al, 2013; San Miguel et al, 2013; San-Miguel et al, 2014; Stewart et al, 2015), it is perhaps surprising that…”
BackgroundResultMcMillin, D. W., Delmore, J., Weisberg, E., Negri, J. M., Geer, D. C., Klippel, S., Mitsiades, N., Schlossman, R. L., Munshi, N. C., Kung, A. L., et al. (2010) · Nature Medicine · doi:10.1038/nm.2112 · Cited by 315
“This further supports the biological significance of stroma-mediated drug resistance, as highlighted in several large randomized clinical trials in M”
ResultPomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6802 · Cited by 317
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
“The largest randomized studies in this setting have employed the newer agents, and include the comparisons of bortezomib against dexamethasone (Richardson et al, 2005), and lenalidomide and dexamethasone against dexamethasone alone (Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundNew criteria for response assessment: role of minimal residual disease in multiple myeloma
Paiva, B., van Dongen, J. J. M., & Orfao, A. (2015) · Blood · doi:10.1182/blood-2014-11-568907 · Cited by 299
Costa, L. J., Brill, I. K., Omel, J., Godby, K., Kumar, S. K., & Brown, E. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016002493 · Cited by 293
Lonial, S., Vij, R., Harousseau, J.-L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X., Tsao, L. C., Westland, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Self-citationLarocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Richardson, P. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481325 · Cited by 290
Panobinostat for the Treatment of Multiple Myeloma
Laubach, J. P., Moreau, P., San-Miguel, J. F., & Richardson, P. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0530 · Cited by 255
Self-citationFacon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271
Self-citationHideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience
Holstein, S. A., & McCarthy, P. L. (2017) · Drugs · doi:10.1007/s40265-017-0689-1 · Cited by 255
NCCN Task Force Report: Management of Neuropathy in Cancer
Stubblefield, M. D., Burstein, H. J., Burton, A. W., Custodio, C. M., Deng, G. E., Ho, M., Junck, L., Morris, G. S., Paice, J. A., Tummala, S., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0078 · Cited by 257
Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group
Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., et al. (2016) · Leukemia · doi:10.1038/leu.2015.356 · Cited by 258
Self-citationWitzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 260
“The overall tolerability profile of lenalidomide was consistent with that shown by lenalidomide therapy in patients with other hematologic disorders.(10-12) Of interest, only one venous thromboembolic event (pulmonary embolus) was reported in a patient who was also experiencing a tumor flare and was not on prophylaxis.”
BackgroundResultSelf-citationKristinsson, S. Y., Pfeiffer, R. M., Björkholm, M., Goldin, L. R., Schulman, S., Blimark, C., Mellqvist, U.-H., Wahlin, A., Turesson, I., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2009-11-252072 · Cited by 255
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Self-citationHabermann, T. M., Lossos, I. S., Justice, G., Vose, J. M., Wiernik, P. H., McBride, K., Wride, K., Ervin‐Haynes, A., Takeshita, K., Pietronigro, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07626.x · Cited by 244
“In clinical trials, lenalidomide has demonstrated activity in relapsed or refractory multiple myeloma when given in combination with dexamethasone (Dimopoulos et al, 2007; Weber et al, 2007), and as single-agent therapy in myelodysplastic syndrome with 5q deletion (List et al, 2006), chronic…”
BackgroundSelf-citationMultiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., San Miguel, J., Ludwig, H., Schouten, H., Mohty, M., Dimopoulos, M., & Dreyling, M. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt297 · Cited by 238
Self-citationOcio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., Kumar, S., Usmani, S., Roodman, D., Niesvizky, R., et al. (2014) · Leukemia · doi:10.1038/leu.2013.350 · Cited by 233
Self-citationAnderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0061 · Cited by 226
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Delforge, M., Bladé, J., Dimopoulos, M. A., Facon, T., Kropff, M., Ludwig, H., Palumbo, A., Van Damme, P., San-Miguel, J. F., & Sonneveld, P. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70068-1 · Cited by 222
Self-citationThe role of complete response in multiple myeloma
Harousseau, J.-L., Attal, M., & Avet-Loiseau, H. (2009) · Blood · doi:10.1182/blood-2009-03-201053 · Cited by 222
Self-citationMultiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2014) · American Journal of Hematology · doi:10.1002/ajh.23810 · Cited by 208
Breitkreutz, I., Raab, M. S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Chauhan, D., Okawa, Y., Munshi, N. C., Richardson, P. G., et al. (2008) · Leukemia · doi:10.1038/leu.2008.174 · Cited by 209
“2 In two large-phase III studies comparing lenalidomidesdexamethasone versus dexamethasone in relapsed MM, extent and frequency of response, as well as progress free and overall survival, were prolonged in the combined therapy cohort”
BackgroundGuidelines for supportive care in multiple myeloma 2011
Snowden, J. A., Ahmedzai, S. H., Ashcroft, J., D’Sa, S., Littlewood, T., Low, E., Lucraft, H., Maclean, R., Feyler, S., Pratt, G., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08574.x · Cited by 206
“Neither drug used as monotherapy significantly increases risk, but when combined with high-dose steroids or cytotoxic agents the risk of VTE increases significantly (Richardson et al, 2006a; Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
“First, lenalidomide (Revlimid, CC-5013, Figure 1b) is approved for the treatment of relapsed multiple myeloma, myelodysplastic syndrome (MDS, particularly those genotyped to a chromosomal 5 truncation) (25), and mantle cell lymphoma.”
BackgroundThe rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 192
“Both studies showed improvement in the primary endpoint of time to progression [Dimopoulos et al. 2007; Weber et al. 2007].”
BackgroundResultLatest advances and current challenges in the treatment of multiple myeloma
Mahindra, A., Laubach, J., Raje, N., Munshi, N., Richardson, P. G., & Anderson, K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.15 · Cited by 201
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Zonder, J. A., Crowley, J., Hussein, M. A., Bolejack, V., Moore, D. F., Whittenberger, B. F., Abidi, M. H., Durie, B. G. M., & Barlogie, B. (2010) · Blood · doi:10.1182/blood-2010-08-303487 · Cited by 194
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Chanan-Khan, A. A., & Giralt, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4250 · Cited by 195
Venous Thromboembolism in the Hematologic Malignancies
Falanga, A., & Marchetti, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8197 · Cited by 192
IRF4: Immunity. Malignancy! Therapy?
Shaffer, A. L., Emre, N. C. T., Romesser, P. B., & Staudt, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1845 · Cited by 189
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, A., Verstovsek, S., Barosi, G., Passamonti, F., Roboz, G. J., Gisslinger, H., Paquette, R. L., Cervantes, F., Rivera, C. E., Deeg, H. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7356 · Cited by 195
“Lenalidomide is approved for use in low/ intermediate-1 risk myelodysplastic syndrome associated with transfusion-dependent anemia and a deletion 5q cytogenetic abnormality(4) and, in combination with dexamethasone, in relapsed multiple myeloma.(5,6) Pomalidomide is currently not US Food and Drug Administration–approv…”
BackgroundCARRIER, M., LE GAL, G., TAY, J., WU, C., & LEE, A. Y. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04215.x · Cited by 193
Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents
Zangari, M., Fink, L. M., Elice, F., Zhan, F., Adcock, D. M., & Tricot, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3875 · Cited by 194
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30124-3 · Cited by 193
Self-citationCancer Therapy–Associated Thrombosis
Grover, S. P., Hisada, Y. M., Kasthuri, R. S., Reeves, B. N., & Mackman, N. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314378 · Cited by 180
Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., Masszi, T., Fontan, J., Michallet, M., Gratwohl, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4918 · Cited by 190
“Our 19-month TTP is, in fact, even longer than the longest TTP recorded so far, namely for lenalidomide-dexamethasone (13 months in the MM-009 and MM-010 trials).(17,18) However, trial comparisons must be viewed with caution because of differences in study populations, dose intensity, or use of maintenance therapy.”
Self-citationPour, L., Sevcikova, S., Greslikova, H., Kupska, R., Majkova, P., Zahradova, L., Sandecka, V., Adam, Z., Krejci, M., Kuglik, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.094409 · Cited by 186
“Even in relapsed disease, remissions can be obtained in the majority of patients [4, 5] although these tend to be shorter than first treatment responses [6, 7].”
BackgroundLopez‐Girona, A., Heintel, D., Zhang, L., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J. B., Schafer, P. H., Schreder, M., Bolomsky, A., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08689.x · Cited by 181
“It is highly active in combination with the corticosteroid dexamethasone in myeloma patients who have received at least one prior therapy (Dimopoulos et al, 2007, 2009, 2011; Weber et al, 2007).”
BackgroundBenson, D. M., Cohen, A. D., Jagannath, S., Munshi, N. C., Spitzer, G., Hofmeister, C. C., Efebera, Y. A., Andre, P., Zerbib, R., & Caligiuri, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0304 · Cited by 180
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
“This spurred the development of more potent and less toxic analogs of thalidomide, including lenalidomide (176, 177) and pomalidomide (178), now approved for the treatment of myeloma.”
BackgroundReece, D., Song, K. W., Fu, T., Roland, B., Chang, H., Horsman, D. E., Mansoor, A., Chen, C., Masih-Khan, E., Trieu, Y., et al. (2009) · Blood · doi:10.1182/blood-2008-12-193458 · Cited by 185
Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
Konopleva, M., Tabe, Y., Zeng, Z., & Andreeff, M. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.06.001 · Cited by 178
Richardson, P. G., Xie, W., Jagannath, S., Jakubowiak, A., Lonial, S., Raje, N. S., Alsina, M., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-517276 · Cited by 182
Self-citationTreatment of relapsed and refractory multiple myeloma
Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 171
“Bortezomib is also effective as part of quadruple drug salvage regimens (ORR 56–88%; CR 6–46%;(VGPR or better 34–55%), and favorable response rates have been reported of bortezomib with CTD (VCTD), VMPT, and bortezomib with doxorubicin, dexamethasone, and lenalidomide (DVD-R).(62,75,76) Bortezomib also appears to enha…”
Proteasome inhibitors in the treatment of multiple myeloma
Shah, J. J., & Orlowski, R. Z. (2009) · Leukemia · doi:10.1038/leu.2009.173 · Cited by 179
Wang, M., Dimopoulos, M. A., Chen, C., Cibeira, M. T., Attal, M., Spencer, A., Rajkumar, S. V., Yu, Z., Olesnyckyj, M., Zeldis, J. B., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141614 · Cited by 176
Self-citationPalumbo, A., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F., Rossini, F., Caltagirone, S., Benevolo, G., Pescosta, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.7561 · Cited by 173
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D’Angelo, C., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0061 · Cited by 161
Progress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 169
Mohty, B., El-Cheikh, J., Yakoub-Agha, I., Moreau, P., Harousseau, J.-L., & Mohty, M. (2010) · Haematologica · doi:10.3324/haematol.2009.012674 · Cited by 167
Self-citation
Metadata
- Authors
- Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, M., Yu, Z., Patin, J., Zeldis, J. B., & Knight, R. D.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- The Alfred Hospital (AU)
- Hôpital Purpan (FR)
- Peter MacCallum Cancer Centre (AU)
- Centre Hospitalier Universitaire de Nantes (FR)
- Gdańsk Medical University (PL)
- Hôpital Claude Huriez (FR)
- Sapienza University of Rome (IT)
- Policlinico San Matteo Fondazione (IT)
- Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine (UA)
- Celgene (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2123-2132
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992538067
- Semantic Scholar
- 32cf6aa2c629905ca550153f79309e6594cf499b
- Cited by
- 1,450
- References
- 17
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 24 · 2023: 55 · 2022: 50 · 2021: 46 · 2020: 59 · 2019: 54 · 2018: 68 · 2017: 87 · 2016: 97 · 2015: 86 · 2014: 90 · 2013: 135 · 2012: 126
- FWCI
- 67.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- lenalidomide, dexamethasone, relapsed/refractory multiple myeloma, thalidomide analogues, time to progression, overall survival, complete response, neutropenia, venous thromboembolism, thrombocytopenia, combination chemotherapy, adverse events, immunomodulators, corticosteroids, treatment efficacy comparison
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunologic Factors, Male, Middle Aged, Multiple Myeloma, Recurrence, Thalidomide, Survival Analysis, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.